IL6 and COVID-19: A recombinant humanized anti-IL-6 receptor monoclonal antibody (Tocilizumab) is being used for treating COVID-19 patients that inhibits the binding of IL-6 to both membrane and soluble IL-6 receptors, blocking IL-6 signaling and reducing inflammation [23].